Head-to-head comparison between plasma p-tau217 and flortaucipir-PET in amyloid-positive patients with cognitive impairment
Abstract Background Plasma phosphorylated tau (p-tau) has emerged as a promising biomarker for Alzheimer’s disease (AD). Studies have reported strong associations between p-tau and tau-PET that are mainly driven by differences between amyloid-positive and amyloid-negative patients. However, the rela...
Main Authors: | Nidhi S. Mundada, Julio C. Rojas, Lawren Vandevrede, Elisabeth H. Thijssen, Leonardo Iaccarino, Obiora C. Okoye, Ranjani Shankar, David N. Soleimani-Meigooni, Argentina L. Lago, Bruce L. Miller, Charlotte E. Teunissen, Hillary Heuer, Howie J. Rosen, Jeffrey L. Dage, William J. Jagust, Gil D. Rabinovici, Adam L. Boxer, Renaud La Joie |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-09-01
|
Series: | Alzheimer’s Research & Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13195-023-01302-w |
Similar Items
-
Tau pathology in neurodegenerative disease: disease mechanisms and therapeutic avenues
by: Niyatee Samudra, et al.
Published: (2023-06-01) -
Head-to-head comparison of relative cerebral blood flow derived from dynamic [18F]florbetapir and [18F]flortaucipir PET in subjects with subjective cognitive decline
by: Hayel Tuncel, et al.
Published: (2023-10-01) -
Tau accumulation in autosomal dominant Alzheimer’s disease: a longitudinal [18F]flortaucipir study
by: Antoinette O’Connor, et al.
Published: (2023-05-01) -
Direct comparison between 18F-Flortaucipir tau PET and quantitative susceptibility mapping in progressive supranuclear palsy
by: Ryota Satoh, et al.
Published: (2024-02-01) -
SPARE-Tau: A flortaucipir machine-learning derived early predictor of cognitive decline.
by: Jon B Toledo, et al.
Published: (2022-01-01)